Determinants of Regional Variation in Health Expenditures in Germany

Health care expenditure in Germany shows clear regional differences. Such geographic variations are often seen as an indicator for inefficiency. With its homogeneous health care system, low co‐payments and uniform prices, Germany is a particularly suited example to analyse regional variations. We use data for the year 2011 on expenditure, utilization of health services and state of health in Germany's statutory health insurance system. This data, which originate from a variety of administrative sources and cover about 90% of the population, are enriched with a wealth of socio‐economic variables, data on pollutants, prices and individual preferences. State of health and demography explains 55% of the differences as measured by the standard deviation while all control variables account for a total of 72% of the differences at county level. With other measures of variation, we can account for an even greater proportion. A higher proportion of variation than usually supposed can thus be explained. Whilst this study cannot quantify inefficiencies, our results contradict the thesis that regional variations reflect inefficiency. Copyright © 2015 John Wiley & Sons, Ltd.     

管理人员职业紧张常模及转换表研制

目的中高层管理人员、一般管理人员职业紧张常模、应用表、分级标准研究。方法采用职业紧张量表(OSI-R),对中高层管理人员263例、一般管理人员569例,共计832例常模样本进行研究。结果首先,采用OSI-R量表分别研制了中高层管理人员、一般管理人员职业紧张常模;其次,在常模的基础上,分别研制了常模样本粗分转换为T分表。职业紧张程度分级职业任务和紧张反应问卷中,T分≥70分者,为高度职业紧张、紧张反应;T分在60分至69分范围内者,为中度职业紧张、紧张反应;T分在40分至59分范围内者,为适度职业紧张和紧张反应;处于正常范围。T分低于40分者,为相对缺乏职业紧张和紧张反应。在应对资源问卷中,T分低于30分者,表明高度缺乏应对资源;T分在30分至39分范围内者,表明中度缺乏应对资源;T分在40分至59分范围之间者,具有适度的应对资源,属于正常范围;T分≥60分者,表明有很强的应对资源。结论将职业紧张的模式结合中高层管理人员、一般管理人员职业紧张常模及应用表,分别针对不同个体主要紧张源、紧张反应、应对资源,采取有针对性的干预(组织、个体)措施,以降低中高层管理人员、一般管理人员职业紧张程度,保护和促进工作能力是职业卫生领域面临的重要任务之一。     

2004年和2005年鲁东大学女教职工妇科查体结果分析

目的通过2004年和2005年本校女教职工妇科查体结果的分析，发现女教职工中未被识别的疾病与致病因子，从而达到防病、治病的目的。通过两年查体结果的分析比较，进一步说明高校女教职工定期进行妇科查体的必要性。方法收集、整理2004年和2005年两年的妇科查体结果，并对不同年龄组的患病率进行分析、比较，查找原因。结果两年的查体结果表明，2005年各年龄段妇科疾病的发病率明显较2004年低，经卡方比较，差异有显著性。结论对女教职工实施定期的妇科查体，对及旱发现妇科疾病、及时进行适当的治疗、保障女教职工的身体健康起了重要作用。     

积极探索我国医疗器械监管新模式

通过借鉴世界发达国家医疗器械监管的特点，分析我国医疗器械监管方法与世界发达国家之间存在的差距，着重阐述医疗器械生产企业监管模式的构建，提出了建立动态化管理、闭环式管理、层次化管理、一体化管理的体系，提出了建立政府告知、企业承诺、符合性评估的企业许可审批制度等监管方式。     

Evaluating the impact of a service fee on patient compliance

This paper addresses an evaluation of an administrative decision to change the manner in which services were paid for at a Student Health Center (SHC). The impact of the change in payment was observed through monitoring the number of scheduled appointments at the SHC which the patient failed to attend, reschedule, or cancel. The impact was assessed through a comparison of the weekly no-show rates from the year prior to the change in payment practices through the year following the change. A time-series statistical package was used to analyze the no-show data. Collateral measures on the number of students attending the university, staff opinions, and usage of the SHC by different student groups were collected. Evaluations of the impact of administrative decisions on health-related behavior were discussed, in addition to a discussion of the usefulness of time-series models for this type of evaluation.     

The Hospital Frailty Risk Score Identifies Fewer Cases of Frailty in a Community-Based Cohort of Older Men Than the FRAIL Scale and Frailty Index

ObjectivesThe recently developed Hospital Frailty Risk Score (HFRS) allows ascertainment of frailty from administrative data. We aimed to compare the HFRS against the widely used FRAIL Scale and Frailty Index.DesignPopulation-based cohort study linked to Western Australian Hospital Morbidity Data Collection and Death Registrations.Setting and ParticipantsThe Health in Men Study with frailty determined at Wave 2 (2001/2004), mortality in the 1-year period following Wave 2, and disability at Wave 3 (2008). Participants were 4228 community-based men aged ≥75 years, followed until Wave 3.MeasurementsWe used multivariable regression to determine the association between each frailty measure and outcomes of length of stay (LOS), death, and disability. We also determined if the additional cases of frailty identified by one measure over the other was associated with these outcomes.ResultsOf 4228 men studied, the HFRS (n = 689) identified fewer men as frail than the FRAIL Scale (n = 1648) and Frailty Index (n = 1820). In the fully adjusted models, all 3 frailty measures were associated with longer LOS and mortality, whereas only the FRAIL Scale and Frailty Index were significantly associated with disability. The additional cases of frailty identified by the FRAIL Scale and Frailty Index had longer LOS and greater risks of death and disability. The fully adjusted hazard ratio for death among the additional cases of frailty identified by the FRAIL Scale (compared to being not frail on both HFRS and FRAIL Scale) was 2.14 (95% CI 1.48-3.08).Conclusions and ImplicationsThe HFRS is associated with adverse outcomes. However, it identified approximately 60% fewer men who were frail than the FRAIL Scale and Frailty Index, and the additional cases identified were also at high risks of adverse outcomes. Users of the HFRS should be aware of the differences with other frailty measures.     

药品行政保护品种介绍:抗感染药物(九)(续八)

甲磺酸曲伐沙星及其Ｔｒｏｖａｎ片剂　通用名 :甲磺酸曲伐沙星 (ｔｒｏｖａｆｌｏｘａｃｉｎｍｅｓｙｌａｔｅ) ,商品名 :Ｔｒｏｖａｎ片剂 ,化学名 :(1α,5α ,6α) 7 (6 氨基 3 氮杂双环[3 ,1 ,0 ] 己 3 基 ) 1 (2 ,4 二氟苯基 ) 6 氟 1 ,4 二氢 4 氧 1 ,8 萘啶 3 羧酸单甲磺酸盐 ,结构式见图 1。　　申请日 :1 998年 3月 1 7日。申请人 :美国辉瑞公司。申请号 :Ａ ＵＳ 980 3 1 70 2。授权日 :1 998年1 0月 2 7日 ,授权号 :Ｂ ＵＳ 981 0 2 71 1。法定行政保护期 :自授权之日起 7.5ａ,到 2 0 0 6年 4月 2 7日。专利介绍 :专利号…     

药品行政保护品种介绍:神经和精神系统药物(一)(待续)

文拉法辛缓释胶囊　通用名 :文拉法辛 (venla faxine)缓释胶囊。商品名 :怡诺思 (Efexor)缓释胶囊。化学名 :(R/S) 1 [2 (二甲胺 ) 1 (4 甲氧苯基 )乙基 ]环己醇盐酸盐。结构式见图 1。图 1　文拉法辛结构式　　　Fig 1　Structureofvenlafaxine　　申请日 :1999年 4月 16日。申请人 :荷兰AHP制药有限公司。申请号 :A NL 990 4 16 10。授权号 :B NL 9912 2 32 1。授权日 :1999年 12月 2 3日。法定行政保护期 :从授权之日起 7.5a ,到 2 0 0 7年 6月2 3日止。专利介绍 :欧洲专利第 0 12 2 6 6 9号。商标注册 :在我国注册的商标为怡诺…     

药品行政保护品种介绍:抗组胺药(一)(待续)

地氯雷他定片剂通用名:地氯雷他定(desloratadine).商品名:Aerius片剂.化学名:8-氯-6,11-二氢-11-(4-哌啶亚基)-5H-苯[5,6]-环庚[1,2-b]吡啶.结构式见图1.